Zacks: Analysts Anticipate ChemoCentryx Inc (NASDAQ:CCXI) to Announce -$0.27 EPS
Equities analysts expect ChemoCentryx Inc (NASDAQ:CCXI) to post earnings of ($0.27) per share for the current quarter, according to Zacks. Six analysts have provided estimates for ChemoCentryx’s earnings, with the highest EPS estimate coming in at ($0.20) and the lowest estimate coming in at ($0.32). ChemoCentryx posted earnings per share of ($0.22) in the same quarter last year, which would suggest a negative year over year growth rate of 22.7%. The company is expected to report its next earnings report on Thursday, November 14th.
According to Zacks, analysts expect that ChemoCentryx will report full-year earnings of ($1.02) per share for the current year, with EPS estimates ranging from ($1.21) to ($0.71). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.31) per share, with EPS estimates ranging from ($2.05) to ($0.46). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for ChemoCentryx.
ChemoCentryx (NASDAQ:CCXI) last released its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). ChemoCentryx had a negative return on equity of 103.61% and a negative net margin of 144.27%. The business had revenue of $7.17 million during the quarter, compared to analysts’ expectations of $10.08 million.
CCXI stock traded down $0.06 during midday trading on Friday, reaching $7.58. The company’s stock had a trading volume of 497,238 shares, compared to its average volume of 310,472. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.57 and a current ratio of 3.57. The stock has a fifty day simple moving average of $7.10 and a two-hundred day simple moving average of $9.99. ChemoCentryx has a 1 year low of $6.16 and a 1 year high of $14.98. The firm has a market capitalization of $443.49 million, a price-to-earnings ratio of -9.97 and a beta of 1.19.
Institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC purchased a new position in shares of ChemoCentryx during the second quarter valued at $29,000. BNP Paribas Arbitrage SA increased its stake in shares of ChemoCentryx by 46,860.0% during the first quarter. BNP Paribas Arbitrage SA now owns 4,696 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 4,686 shares during the period. Quantamental Technologies LLC purchased a new position in shares of ChemoCentryx during the second quarter valued at $46,000. Aperio Group LLC purchased a new position in shares of ChemoCentryx during the second quarter valued at $82,000. Finally, JPMorgan Chase & Co. increased its stake in shares of ChemoCentryx by 104.2% during the second quarter. JPMorgan Chase & Co. now owns 11,191 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 5,710 shares during the period. Hedge funds and other institutional investors own 64.27% of the company’s stock.
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
Featured Article: What is Net Asset Value (NAV)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.